Clinical Trial Update: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated a fixed-dose combination of ledipasvir/sofosbuvir given for 12 weeks in adults with chronic genotype 2 HCV infection; the study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-03-14